DOCSLIB.ORG

Deafness Caused by Ototoxicity in Developing Countries

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Deafness Caused by Ototoxicity in Developing Countries 2006; 3:17-32 Issue No. 4 EDITORIAL: OTOTOXICITY Ian J Mackenzie MD MSc ical experimentation and a careful and accurate Liverpool School of Tropical Medicine recording system of any Pembroke Place side effects a drug gener- Liverpool L3 5QA ates. Subtle side effects, UK like tinnitus and deafness, are not identified until Email: [email protected] many people are affected and it is reported in the he majority of illnesses world- medical literature. It is wide are treated with medication. difficult, particularly in TMedicines have been used in the animal experiments, to treatment of illness for hundreds of years. record tinnitus or deafness The medicines of today are sophisticated as a side effect of a drug, and their development is at the forefront even though the hearing of science. Medicines have eradicated and balance systems are some diseases and controlled others. The anatomically very delicate Teaching and learning at a School for the Deaf in Afghanistan successful conquering of some cancers, and sensitive to toxins. previously thought untreatable, show Photo: SHIP/CBM the ingenuity and science that has been Ototoxicity the problem may be whether or not to part of their development. However, the The term ototoxicity covers any damage prescribe certain essential drugs know- development of new drugs takes a long to hearing and balance caused by a toxin, ing that there is a high chance of leav- time and is a very expensive process. as it affects the end organs of the eighth ing the patient with a long term hearing deficit. There is little information on the Side Effects of Medicines cranial nerve. The toxin can enter the body by ingestion, inhalation or with side effects of herbal and homeopathic Drugs of all sorts have known side effects skin contact. When a patient needs life- medication. which can only be discovered by clin- saving medication for severe illness, The long term cost to the community CONTENTS of ototoxicity is not known but hearing impairment, deafness, tinnitus or dizzi- Community Ear and Hearing Health 2006; 3:17-32 Issue No.4 ness can cause difficulties with language EDITORIAL Ian J Mackenzie 17 development and learning in children, LEAD ARTICLES: OTOTOXICITY and with work communication and Deafness Caused by Ototoxicity in Developing Rajan N Patel 18 performance. Countries Solvent Exposure at the Workplace: Adrian Fuente 22 In many instances, these side effects are Workers’ Hearing in Jeopardy not present if drugs are prescribed prop- erly. Some drugs may interact with each Ototoxicity: A Canadian View Peter W Alberti 24 other and lead to increased toxicity, but Molecular Diagnosis of Mitochondrial Genes: Min-Xin Guan 25 these interactions are not well under- Early Detection and Prevention of Aminoglycoside stood. When the cause of deafness is not Ototoxicity identified, it is important to review occu- REPORTS pation and medication to see if there is The Need of a Programme for the Prevention of Diego J Santana-Hernández 28 any toxin responsible for the deafness. Hearing Impairment in Beni State, Bolivia Ototoxicity is more common than often Atfaluna News Update Geraldine Shawa 30 suggested and in most cases is a prevent- ABSTRACTS 31 able cause of deafness. COMMUNITY EAR AND HEARING HEALTH: 2006; 3: 17-32 Issue No. 4 www.icthesworldcare.com 17 Ototoxicity in Developing Countries DEAFNESS CAUSED BY OTOTOXICITY IN DEVELOPING COUNTRIES Rajan N Patel Table 1: Grades of Hearing Impairment Medical Student Grade of impairment Corresponding audiometric ISO* value Department of Child and Reproductive 0 - None 25 dB or better Health 1 – Slight 26-40 dB Liverpool School of Tropical Medicine Pembroke Place 2 – Moderate 41-60 dB Liverpool L3 5QA 3 - Severe 61-80 dB UK 4 – Profound 81 dB or greater *International Organization for Standardization Email: [email protected] his report attempts to review million people in the world had a disa- Grades of Hearing Impairment systematically the current liter- bling hearing impairment and that two- Deafness can be expressed as a complete ature on deafness caused by thirds of these people lived in develop- loss in the ability to hear from one or T ing countries.2 Furthermore, Torrigiani ototoxicity in developing countries and both ears. It can also be described as a make an appraisal of its current status in Geneva outlined that avoidable hearing threshold of 81dB or greater, in different regions of the developing hearing impairment and deafness are averaged at frequencies 0.5, 1, 2, 4 kHz.2 world. This involves critically assessing an important public health problem, Table 1 provides the different grades of research and accessing routine electronic particularly in low-income countries. hearing impairment.2 literature databases. Although infectious conditions, such as otitis media, account for the largest Ototoxicity and its Causes Deafness Worldwide proportion of conductive hearing loss, Ototoxicity refers to the harmful effect Deafness is a worldwide problem. It is damage to sensori-neural hearing caused of a drug, chemical substance or heavy estimated that 1:1000 children are born by ototoxic medication has been increas- metal on the organ of hearing or balance, deaf, while 2:1000 children are born ingly reported from countries in recent which may lead to a hearing impair- 3 hard of hearing.1 In 2002, the World years. ment, and/or balance problems. Table 2 Health Organization estimated that 250 displays some of these substances.3 Table 2: Causes of Hearing Impairment and/or Balance Problems Aminoglycosides Gentamicin, streptomycin, kanamycin, amikacin, tobramycin, neomycin, netilmicin, polymyxin-B Macrolides Erythromycin, azithromycin, clarithromycin Loop diuretics Furosemide, bumetanide, ethacrinic acid Salicylates Antimalarials Quinine, chloroquine (high dosage) Non-steroid anti-inflammatory drugs Naproxen, indomethacin (no definite findings) Anti-neoplastic drugs Cisplatin, bleomycin, carboplatinum Chelating agents Desferoxamine Topical otological preparations Antibiotic solutions: Neomycin Aminoglycosides Polymyxin-B Chloramphenicol Fosfomycin Anti-inflammatory: Propylene-glycol, hydrocortisone Antiseptic: Chlorohexidine, povidone-iodine (?) Acidifying: 2% acetic acid solution (?) Chemical agents Heavy metals: Mercury, lead (Industrial pollution, cosmetics). Solvents: Toluene, styrene Others: Arsenic, cobalt, cyanides, benzene, propylene-glycol, potassium bromide 18 www.icthesworldcare.com COMMUNITY EAR AND HEARING HEALTH: 2006; 3: 17-32 Issue No. 4 Ototoxicity in Developing Countries Ototoxicity tends to be thought of in caused by the prescription of ototoxic which the main criterion for classify- the context of drug administration lead- drugs, one should assume that preven- ing economies is gross national income ing to damage of the cochlea or vestib- tive measures could be taken effectively. (GNI) per capita. Based on its GNI per ular portion of the inner ear, causing Minja makes reference to the prevent- capita, every economy is classified as transitional or permanent sensorineural ability of deafness due to ototoxicity, low income, middle income (subdivided hearing loss (SNHL) and/or vertigo. despite its variety of causes.1 Suggestions into lower middle and upper middle), Antibiotics, diuretics and anti-malarial will be made regarding methods and or high income. Table 3 identifies some pharmaceuticals have been implicated strategies for the prevention of ototoxic- of the developing countries that will be as potentially toxic to both the auditory ity in developing countries. discussed in this report, and others that and vestibular systems. Kanamycin and are noteworthy.7 neomycin are perhaps the most alarm- Another report refers to the extensive use ing ototoxic drugs at this time.4 This and abuse of aminoglycosides and how To summarise this introduction to report will later discuss and evaluate the they are a major concern.3 It suggests ototoxicity-induced deafness, it is impor- current status of ototoxicity due to these that the most common cause of hearing tant to note that the global magnitude of substances. This will be accomplished by impairment from ototoxic damage by the problem is not accurately known assessing and reviewing different litera- drugs is due to injectable aminoglyco- and that there is a great need for more ture written about the use of these chem- sides. It is also implied that gentamicin detailed research on ototoxicity. icals in various regions of the world, and is cheaper than newly available alterna- in particular, the developing world. tives and, hence, is more widely avail- Discussion and Results able. Additionally, WHO recognises that This report will now analyse and review While aminoglycosides have been largely the global resurgence of tuberculosis is the literature found. It will discuss the replaced over the last decades by modern leading to greater use of streptomycin.3 current status of ototoxicity in develop- antibiotics with fewer side effects, they For example, in South Africa, strepto- ing countries by comparing results from remain a mainstay in medicine. In fact, mycin and kanamycin form part of the clinical studies carried out. It will then they may be the most commonly used drug regimen administered to multi- assess the disagreements, strengths and antibiotics worldwide, chiefly due to drug resistant tuberculosis (MDR-TB) weaknesses of various papers. The prob- their use in developing countries. Their sufferers.6 One of the aims of this report lems facing people in developing coun- high efficacy, coupled with
Load more

Recommended publications
  • NVA237 / Glycopyrronium Bromide Multinational, Multi-Database Drug
    Quantitative Safety & Epidemiology NVA237 / Glycopyrronium bromide Non-interventional Final Study Report NVA237A2401T Multinational, multi-database drug utilization study of inhaled NVA237 in Europe Author Document Status Final Date of final version 28 April 2016 of the study report EU PAS register ENCEPP/SDPP/4845 number Property of Novartis Confidential May not be used, divulged, published or otherwise disclosed without the consent of Novartis NIS Report Template Version 2.0 August-13-2014 Novartis Confidential Page 2 Non-interventional study report NVA237A/Seebri® Breezhaler®/CNVA237A2401T PASS information Title Multinational, multi-database drug utilization study of inhaled NVA237 in Europe –Final Study Report Version identifier of the Version 1.0 final study report Date of last version of 28 April 2016 the final study report EU PAS register number ENCEPP/SDPP/4845 Active substance Glycopyrronium bromide (R03BB06) Medicinal product Seebri®Breezhaler® / Tovanor®Breezhaler® / Enurev®Breezhaler® Product reference NVA237 Procedure number SeebriBreezhaler: EMEA/H/C/0002430 TovanorBreezhaler: EMEA/H/C/0002690 EnurevBreezhaler: EMEA/H/C0002691 Marketing authorization Novartis Europharm Ltd holder Frimley Business Park Camberley GU16 7SR United Kingdom Joint PASS No Research question and In the context of the NVA237 marketing authorization objectives application, the Committee for Medicinal Products for Human Use (CHMP) recommended conditions for marketing authorization and product information and suggested to conduct a post-authorization
    [Show full text]
  • Anew Drug Design Strategy in the Liht of Molecular Hybridization Concept
    www.ijcrt.org © 2020 IJCRT | Volume 8, Issue 12 December 2020 | ISSN: 2320-2882 “Drug Design strategy and chemical process maximization in the light of Molecular Hybridization Concept.” Subhasis Basu, Ph D Registration No: VB 1198 of 2018-2019. Department Of Chemistry, Visva-Bharati University A Draft Thesis is submitted for the partial fulfilment of PhD in Chemistry Thesis/Degree proceeding. DECLARATION I Certify that a. The Work contained in this thesis is original and has been done by me under the guidance of my supervisor. b. The work has not been submitted to any other Institute for any degree or diploma. c. I have followed the guidelines provided by the Institute in preparing the thesis. d. I have conformed to the norms and guidelines given in the Ethical Code of Conduct of the Institute. e. Whenever I have used materials (data, theoretical analysis, figures and text) from other sources, I have given due credit to them by citing them in the text of the thesis and giving their details in the references. Further, I have taken permission from the copyright owners of the sources, whenever necessary. IJCRT2012039 International Journal of Creative Research Thoughts (IJCRT) www.ijcrt.org 284 www.ijcrt.org © 2020 IJCRT | Volume 8, Issue 12 December 2020 | ISSN: 2320-2882 f. Whenever I have quoted written materials from other sources I have put them under quotation marks and given due credit to the sources by citing them and giving required details in the references. (Subhasis Basu) ACKNOWLEDGEMENT This preface is to extend an appreciation to all those individuals who with their generous co- operation guided us in every aspect to make this design and drawing successful.
    [Show full text]
  • European Surveillance of Healthcare-Associated Infections in Intensive Care Units
    TECHNICAL DOCUMENT European surveillance of healthcare-associated infections in intensive care units HAI-Net ICU protocol Protocol version 1.02 www.ecdc.europa.eu ECDC TECHNICAL DOCUMENT European surveillance of healthcare- associated infections in intensive care units HAI-Net ICU protocol, version 1.02 This technical document of the European Centre for Disease Prevention and Control (ECDC) was coordinated by Carl Suetens. In accordance with the Staff Regulations for Officials and Conditions of Employment of Other Servants of the European Union and the ECDC Independence Policy, ECDC staff members shall not, in the performance of their duties, deal with a matter in which, directly or indirectly, they have any personal interest such as to impair their independence. This is version 1.02 of the HAI-Net ICU protocol. Differences between versions 1.01 (December 2010) and 1.02 are purely editorial. Suggested citation: European Centre for Disease Prevention and Control. European surveillance of healthcare- associated infections in intensive care units – HAI-Net ICU protocol, version 1.02. Stockholm: ECDC; 2015. Stockholm, March 2015 ISBN 978-92-9193-627-4 doi 10.2900/371526 Catalogue number TQ-04-15-186-EN-N © European Centre for Disease Prevention and Control, 2015 Reproduction is authorised, provided the source is acknowledged. TECHNICAL DOCUMENT HAI-Net ICU protocol, version 1.02 Table of contents Abbreviations ...............................................................................................................................................
    [Show full text]
  • Summary Report on Antimicrobials Dispensed in Public Hospitals
    Summary Report on Antimicrobials Dispensed in Public Hospitals Year 2014 - 2016 Infection Control Branch Centre for Health Protection Department of Health October 2019 (Version as at 08 October 2019) Summary Report on Antimicrobial Dispensed CONTENTS in Public Hospitals (2014 - 2016) Contents Executive Summary i 1 Introduction 1 2 Background 1 2.1 Healthcare system of Hong Kong ......................... 2 3 Data Sources and Methodology 2 3.1 Data sources .................................... 2 3.2 Methodology ................................... 3 3.3 Antimicrobial names ............................... 4 4 Results 5 4.1 Overall annual dispensed quantities and percentage changes in all HA services . 5 4.1.1 Five most dispensed antimicrobial groups in all HA services . 5 4.1.2 Ten most dispensed antimicrobials in all HA services . 6 4.2 Overall annual dispensed quantities and percentage changes in HA non-inpatient service ....................................... 8 4.2.1 Five most dispensed antimicrobial groups in HA non-inpatient service . 10 4.2.2 Ten most dispensed antimicrobials in HA non-inpatient service . 10 4.2.3 Antimicrobial dispensed in HA non-inpatient service, stratified by service type ................................ 11 4.3 Overall annual dispensed quantities and percentage changes in HA inpatient service ....................................... 12 4.3.1 Five most dispensed antimicrobial groups in HA inpatient service . 13 4.3.2 Ten most dispensed antimicrobials in HA inpatient service . 14 4.3.3 Ten most dispensed antimicrobials in HA inpatient service, stratified by specialty ................................. 15 4.4 Overall annual dispensed quantities and percentage change of locally-important broad-spectrum antimicrobials in all HA services . 16 4.4.1 Locally-important broad-spectrum antimicrobial dispensed in HA inpatient service, stratified by specialty .
    [Show full text]
  • Visão De Futuro Para Produção De Antibióticos: Tendências De Pesquisa, Desenvolvimento E Inovação
    UNIVERSIDADE FEDERAL DO RIO DE JANEIRO CRISTINA D’URSO DE SOUZA MENDES SANTOS VISÃO DE FUTURO PARA PRODUÇÃO DE ANTIBIÓTICOS: TENDÊNCIAS DE PESQUISA, DESENVOLVIMENTO E INOVAÇÃO Rio de Janeiro EQ/UFRJ 2014 CRISTINA D ’U RSO DE SOUZA MENDES SANTOS VISÃO DE FUTURO PARA A PRODUÇÃO DE ANTIBIÓTICOS: TENDÊNCIAS DE PESQUISA, DESENVOLVIMENTO E INOVAÇÃO Tese de Doutorado apresentada ao Programa de Pós-Graduação em Tecnologia de Processos Químicos e Bioquímicos, Escola de Química, Universidade Federal do Rio de Janeiro, como requisito parcial à obtenção do título de Doutor em Ciências, D.Sc. Orientadora: Profa. Adelaide Maria de Souza Antunes, D.Sc. Rio de Janeiro 2014 Santos, Cristina d’Urso de Souza Mendes. Visão de futuro para produção de antibióticos: tendências de pesquisa, desenvolvimento e inovação / Cristina d’Urso de Souza Mendes Santos. - Rio de Janeiro, 2014. 216 f.: il.; 29,7 cm. Tese (Doutorado em Ciências) – Universidade Federal do Rio de Janeiro, Escola de Química, Programa de Pós-Graduação em Tecnologia de Processos Químicos e Bioquímicos, Rio de Janeiro, 2014. Orientadora: Adelaide Maria de Souza Antunes. 1. Antibióticos. 2. P&D na Indústria Farmacêutica. 3. Prospecção Tecnológica. 4. Patentes. I. Antunes, Adelaide Maria de Souza. II. Universidade Federal do Rio de Janeiro. Escola de Química. III. Visão de futuro para a produção de antibióticos: tendências de pesquisa, desenvolvimento e inovação. iv v Dedico esta tese à minha mãe querida e amada, que está no céu comemorando esta vitória, que é mais dela do que minha. Dedico também à minha filhinha Malu que sem entender foi a minha maior motivação para concluir esta tese.
    [Show full text]
  • Primary Target Prediction of Bioactive Molecules from Chemical Structure
    bioRxiv preprint doi: https://doi.org/10.1101/413237; this version posted September 10, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license. Primary Target Prediction of Bioactive Molecules from Chemical Structure Abed Forouzesh1, Sadegh Samadi Foroushani1,*, Fatemeh Forouzesh2, and Eskandar Zand1 1Iranian Research Institute of Plant Protection, Agricultural Research Education and Extension Organization (AREEO), Tehran, Iran 2Department of Medicine, Tehran Medical Branch, Islamic Azad University, Tehran, Iran *To whom correspondence should be addressed. Tel: (+9821) 22400080; Fax: (+9821) 22400568; Email: [email protected] ABSTRACT There are various tools for computational target prediction of bioactive molecules from a chemical structure in a machine-readable material but these tools can’t distinguish a primary target from other targets. Also, due to the complex nature of bioactive molecules, there has not been a method to predict a target and or a primary target from a chemical structure in a non-digital material (for example printed or hand-written documents) yet. In this study, an attempt to simplify primary target prediction from a chemical structure was resulted in developing an innovative method based on the minimum structure which can be used in both formats of non-digital and machine-readable materials. A minimum structure does not represent a real molecule or a real association of functional groups, but is a part of a molecular structure which is necessary to ensure the primary target prediction of bioactive molecules.
    [Show full text]
  • Common Study Protocol for Observational Database Studies WP5 – Analytic Database Studies
    Arrhythmogenic potential of drugs FP7-HEALTH-241679 http://www.aritmo-project.org/ Common Study Protocol for Observational Database Studies WP5 – Analytic Database Studies V 1.3 Draft Lead beneficiary: EMC Date: 03/01/2010 Nature: Report Dissemination level: D5.2 Report on Common Study Protocol for Observational Database Studies WP5: Conduct of Additional Observational Security: Studies. Author(s): Gianluca Trifiro’ (EMC), Giampiero Version: v1.1– 2/85 Mazzaglia (F-SIMG) Draft TABLE OF CONTENTS DOCUMENT INFOOMATION AND HISTORY ...........................................................................4 DEFINITIONS .................................................... ERRORE. IL SEGNALIBRO NON È DEFINITO. ABBREVIATIONS ......................................................................................................................6 1. BACKGROUND .................................................................................................................7 2. STUDY OBJECTIVES................................ ERRORE. IL SEGNALIBRO NON È DEFINITO. 3. METHODS ..........................................................................................................................8 3.1.STUDY DESIGN ....................................................................................................................8 3.2.DATA SOURCES ..................................................................................................................9 3.2.1. IPCI Database .....................................................................................................9
    [Show full text]
  • Disease Associated with Pneumocystis Pneumonia In
    J Clin Pathol: first published as 10.1136/jcp.13.1.1 on 1 January 1960. Downloaded from J. clin. Path. (1960), 13, 1. GENERALIZED CYTOMEGALIC INCLUSION-BODY DISEASE ASSOCIATED WITH PNEUMOCYSTIS PNEUMONIA IN ADULTS A REPORT OF THREE CASES, WITH WEGENER'S GRANULOMATOSIS, THROMBOTIC PURPURA, AND HODGKIN'S DISEASE AS PREDISPOSING CONDITIONS BY W. ST. C. SYMMERS From Charing Cross Hospital and Medical School, London (RECEIVED FOR PUBLICATION JULY 4, 1959) Three cases of generalized cytomegalic inclusion-body disease (salivary virus disease) in adults are reported, bringing the number of published cases up to 34. The infection is very rare in adults although well known in infants. As is often found in infants with this disease, pneumonia due to Pneumocystis carinii was also present in each case. The first patient had Wegener's granulomatosis, which presented with acute otitis media: a copyright. review of histological material obtained at mastoidectomy eight weeks before death showed that inclusion-body cytomegaly was already present then. Various antibiotics and prednisolone were given, and the lesions in the respiratory organs and the arteritis healed to a considerable extent. Renal failure, however, was progressive and led to death. The second patient had thrombotic purpura and died after a few weeks' illness, during which oxytetracycline and hydrocortisone were given. Congenital absence of the spleen was found at laparotomy, which was performed with the object of doing a splenectomy. Focal cryptococcal http://jcp.bmj.com/ pneumonia was present post mortem: six years before death a solitary cryptococcal granuloma of one lung had been treated by lobectomy. The third patient had had Hodgkin's disease for 18 years.
    [Show full text]
  • Dostupnost Antiinfektiv V České Republice
    aktuálně ročník 27 | číslo 5/2017 LÉKY A PRÁVO Dostupnost antiinfektiv v České republice MVDr. Veronika Valdová Arete‑Zoe, LLC Souhrn Valdová V. Dostupnost antiinfektiv v České republice. Remedia 2017; 27: 509–513. na Seznamu nepostradatelných léčiv Světové zdravotnické organizace figuruje 119 antiinfektiv, z nichž v České republice není registrováno 29. Dalších 10 léčiv je registrováno, ale neobchodováno. Dostupnost antibiotik a dalších nezbytných léčiv má přímý dopad na klinickou praxi. Příkladem je aktuali- zovaný postup pro léčbu sepse a septického šoku, který doporučuje deeskalaci a zacílení na identifikovaný patogen ihned po jeho identifikaci z důvodu snížení zátěže pro organismus pacienta. aktualizované léčebné postupy je nutno brát v úvahu při sestavování národních seznamů nepostradatelných léčiv. Z nepostradatelných tuberkulostatik a antivirotik chybějí v ČR některé fixní kombinace určené pro první linii léčby tuberkulózy a HIV/aIDS. Padělky léčivých přípravků a nedoléčené infekce jsou hlavními příčinami vzniku multirezistentních kmenů původce tuberkulózy. Z hyperimunních sér v ČR chybí sérum proti záškrtu. Vakcíny se potýkají s celosvětovým nedostatkem v důsledku délky a náročnosti výroby. Klíčová slova: antiinfektiva – nepostradatelná léčiva – dostupnost léčiv – nedostatek léčiv – tuberkulóza – HIV/aIDS – sepse. Summary Valdova V. Availability of antiinfectives in the Czech Republic. Remedia 2017; 27: 509–513. the World Health Organization (WHO) lists 119 antiinfectives on the list of essential medicines. Of these, 29 are not registered in the Czech Republic, and another 10 are registered but not marketed. availability of antimicrobials and other essential medicines directly affects clinical practice. One such example is the newly revised guidelines for the treatment of sepsis and septic shock, which recommends deescalation of antibiotic treatment and targeting the causative pathogen immediately after its identification to minimize toxicity to the patient’s metabolism.
    [Show full text]
  • Point Prevalence Survey of Healthcare-Associated Infections and Antimicrobial Use in European Acute Care Hospitals
    TECHNICAL DOCUMENT Point prevalence survey of healthcare-associated infections and antimicrobial use in European acute care hospitals Protocol version 5.3 www.ecdc.europa.eu ECDC TECHNICAL DOCUMENT Point prevalence survey of healthcare- associated infections and antimicrobial use in European acute care hospitals Protocol version 5.3, ECDC PPS 2016–2017 Suggested citation: European Centre for Disease Prevention and Control. Point prevalence survey of healthcare- associated infections and antimicrobial use in European acute care hospitals – protocol version 5.3. Stockholm: ECDC; 2016. Stockholm, October 2016 ISBN 978-92-9193-993-0 doi 10.2900/374985 TQ-04-16-903-EN-N © European Centre for Disease Prevention and Control, 2016 Reproduction is authorised, provided the source is acknowledged. ii TECHNICAL DOCUMENT PPS of HAIs and antimicrobial use in European acute care hospitals – protocol version 5.3 Contents Abbreviations ............................................................................................................................................... vi Background and changes to the protocol .......................................................................................................... 1 Objectives ..................................................................................................................................................... 3 Inclusion/exclusion criteria .............................................................................................................................. 4 Hospitals .................................................................................................................................................
    [Show full text]
  • Statistical Analysis Plan / Data Specifications the Risk of Acute Liver Injury Associated with the Use of Antibiotics. a Replica
    WP6 validation on methods involving an extended audience Statistical analysis plan / data specifications The risk of acute liver injury associated with the use of antibiotics. A replication study in the Utrecht Patient Oriented Database Version: July 11, 2013 Authors: Renate Udo, Marie L De Bruin Reviewers: Work package 6 members (David Irvine, Stephany Tcherny-Lessenot) 1 1. Context The study described in this protocol is performed within the framework of PROTECT (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium). The overall objective of PROTECT is to strengthen the monitoring of the benefit-risk of medicines in Europe. Work package 6 “validation on methods involving an extended audience” aims to test the transferability/feasibility of methods developed in other WPs (in particular WP2 and WP5) in a range of data sources owned or managed by Consortium Partners or members of the Extended Audience. The specific aims of this study within WP6 are: to evaluate the external validity of the study protocol on the risk of acute liver injury associated with the use of antibiotics by replicating the study protocol in another database, to study the impact of case validation on the effect estimate for the association between antibiotic exposure and acute liver injury. Of the selected drug-adverse event pairs selected in PROTECT, this study will concentrate on the association between antibiotic use and acute liver injury. On this topic, two sub-studies are performed: a descriptive/outcome validation study and an association study. The descriptive/outcome validation study has been conducted within the Utrecht Patient Oriented Database (UPOD).
    [Show full text]
  • Texto Parcial (1.265Mb)
    UNIVERSIDADE FEDERAL DO RIO GRANDE DO SUL FACULDADE DE ODONTOLOGIA PROGRAMA DE PÓS-GRADUAÇÃO EM ODONTOLOGIA Karen Barea de Paula Duarte PRESCRIÇÃO DE ANTIMICROBIANOS EM UM MUNICÍPIO DO SUL DO BRASIL: um estudo retrospectivo em um corte temporal Porto Alegre/RS 2020 Karen Barea de Paula Duarte PRESCRIÇÃO DE ANTIMICROBIANOS EM UM MUNICÍPIO DO SUL DO BRASIL: um estudo retrospectivo em um corte temporal Tese apresentada ao Programa de Pós- Graduação em Odontologia da Faculdade de Odontologia da Universidade Federal do Rio Grande do Sul, como parte dos requisitos para obtenção do título de Doutor em Odontologia. Área de Concentração: Clínica Odontológica/ Endodontia Linha de Pesquisa: Epidemiologia, Etiopatogenia e Repercussão das Doenças da Cavidade Bucal e Estruturas Anexas Orientador: Prof. Dr. Francisco Montagner Porto Alegre/RS 2020 Dedico esse trabalho ao meu pai, Agenor Teixeira de Paula (in memoriam). AGRADECIMENTOS Quando penso em tudo o que aconteceu na minha vida, se eu tirasse Deus da equação, a conta jamais fecharia, portanto, meu maior agradecimento é a Ele, ao meu Senhor Jesus. Agradeço aos meus amados pais. À minha mãe, Maria Salete Barea, pelo amor, resiliência e dedicação...a frase que reverbera em mim, “Karen, vai estudar!”. Ao meu pai, Agenor Teixeira de Paula (in memoriam), por ter me dado condições de chegar até aqui, sem a sua presença física, porém por meio do legado que me foi deixado. Concluir esta etapa não foi fácil, mas foi possível graças ao amor e aos ensinamentos que ficaram em mim. Meu amor e saudades são eternos... Ao amor da minha vida, Antônio Rocir Gonçalves Duarte Júnior, meu marido e parceiro dessa jornada.
    [Show full text]